Cargando…
Live-attenuated H1N1 influenza vaccine candidate displays potent efficacy in mice and ferrets
Currently, influenza vaccine manufacturers need to produce 1–5 x 10(7) PFU of each vaccine strain to fill one dose of the current live-attenuated-influenza-vaccine (LAIV). To make a single dose of inactivated vaccine (15 ug of each hemagglutinin), the equivalent of 10(10) PFU of each vaccine strains...
Autores principales: | Stauft, Charles B., Yang, Chen, Coleman, J. Robert, Boltz, David, Chin, Chiahsuan, Kushnir, Anna, Mueller, Steffen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791556/ https://www.ncbi.nlm.nih.gov/pubmed/31609986 http://dx.doi.org/10.1371/journal.pone.0223784 |
Ejemplares similares
-
Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy
por: Wang, Ying, et al.
Publicado: (2021) -
Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets
por: Suguitan, Amorsolo L, et al.
Publicado: (2006) -
Severity of heterosubtypic influenza virus infection in ferrets is reduced by live attenuated influenza vaccine
por: Marriott, Anthony C., et al.
Publicado: (2021) -
584. Phase 1 Placebo-Controlled Trial of COVI-VAC™, an Intranasal, Live Attenuated COVID-19 Vaccine
por: Tasker, Sybil, et al.
Publicado: (2021) -
Sequential Immunization with Universal Live Attenuated Influenza Vaccine Candidates Protects Ferrets against a High-Dose Heterologous Virus Challenge
por: Isakova-Sivak, Irina, et al.
Publicado: (2019)